Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 5, 2012, Pages 324-328

  Liu, Caigang ^a   Luo, Yang ^b   Liu, Xing ^b   Lu, Ping ^a   Zhao, Zuowei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

breast cancer; cancer stem cell; chemoradiotherapy sensitivity; survival

Indexed keywords

CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER STEM CELL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862499348     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1155     Document Type: Article

References (16)

1. Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R. for the International Cancer Screening Network (ICSN): Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen 2010;17:139-146.
2. Gaffan J, Dacre J, Jones A. Educating undergraduate medical students about oncology: A literature review. J Clin Oncol 2006;24:1932-1939. (Pubitemid 46638993)
3. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011;29:1664-1669.
4. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-3277.
5. Shan J, Shen J, Liu L, et al. Nanog regulates self-renewal of cancer stem cell through IGF pathway in human hepatocellular carcinoma. Hepatology 2012 [Epub ahead of print]; Doi: 10.1002/hep.25745.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3547-3549.
7. Lee HE, Kim JH, Kim YJ, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011;104:1730-1738.
8. Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005;11:1154-1159.
9. Liu R, Wang X, Chen G Y, et al. The prognostic role of a gene signature from tumorigenec breast-cancer cells. N Engl J Med 2007;356:217-26. (Pubitemid 46143225)
10. Wright MH, Calcaqno AM, Varticovski L, et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
11. Sheridan C, Kishimoto H, Nakshatri H, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
12. Shackleton M, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006;439:84-88. (Pubitemid 43053633)
13. Stingl J. Purification and unique properties of mammary epithelial stem cells. Nature 2006;439:993-997. (Pubitemid 43292419)
14. Liu CG, Lu Y, Wang BB, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg 2011;253:1165-1171.
15. Buess M, Rajski M, Vogel-Durrer BM, et al. Tumorendothelial interaction links the CD44+/CD24- phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009;11:987-1002.
16. Ali HR, Dawson SJ, Blows FM, et al. Cancer stem cell markers in breast cancer: Pathological, clinical and prognostic significance. Breast Cancer Res 2011;13:R118.